Specify a stock or a cryptocurrency in the search bar to get a summary
Talphera Inc.
TLPHTalphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California. Address: 1850 Gateway Drive, San Mateo, CA, United States, 94404
Analytics
WallStreet Target Price
4.17 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures TLPH
Dividend Analytics TLPH
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History TLPH
Stock Valuation TLPH
Financials TLPH
Results | 2019 | Dynamics |